View in EDS HTML Full Text

Confluence Genetics Launches Cas-CLEAR™, a New CRISPR Technology Platform for Cancer Therapy

Saved in:
Bibliographic Details
Title: Confluence Genetics Launches Cas-CLEAR™, a New CRISPR Technology Platform for Cancer Therapy
Authors: Confluence Genetics
Source: Business Wire (English). 07/09/2026.
Abstract: Confluence Genetics today announced the launch of Cas-CLEAR™, Collaterally Enhanced Activated Ribonuclease, a new CRISPR technology platform for the treatment of cancers carrying defined genetic signatures, with lead programs in development for hepatocellular carcinoma (HCC). Unlike gene editing CRISPR systems that cut and modify DNA at a single site, Cas-CLEAR uses Cas12a2 nucleases to recognize cancer-specific genetic signatures and trigger broad collateral cleavage of cellular DNA and RNA, resulting in the selective elimination of cells carrying the targeted signature. The launch coincides with two independent Nature publications validating the platform’s selective cancer cell-killing mechanism: a peer-reviewed publication from the laboratory of Nobel laureate Jennifer Doudna at the University of California, Berkeley featuring in vivo mouse model data, and another led by researchers at Utah State University and University of Utah Health. [ABSTRACT FROM PUBLISHER]
Database: Regional Business News
Full text is not displayed to guests.
FullText Text:
  Availability: 1
Header DbId: bwh
DbLabel: Regional Business News
An: bizwire.20260709876340
AccessLevel: 6
PubType: News
PubTypeId: newspaperArticle
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Confluence Genetics Launches Cas-CLEAR™, a New CRISPR Technology Platform for Cancer Therapy
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Confluence+Genetics%22">Confluence Genetics</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Business+Wire+%28English%29%22">Business Wire (English)</searchLink>. 07/09/2026.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Confluence Genetics today announced the launch of Cas-CLEAR™, Collaterally Enhanced Activated Ribonuclease, a new CRISPR technology platform for the treatment of cancers carrying defined genetic signatures, with lead programs in development for hepatocellular carcinoma (HCC). Unlike gene editing CRISPR systems that cut and modify DNA at a single site, Cas-CLEAR uses Cas12a2 nucleases to recognize cancer-specific genetic signatures and trigger broad collateral cleavage of cellular DNA and RNA, resulting in the selective elimination of cells carrying the targeted signature. The launch coincides with two independent Nature publications validating the platform’s selective cancer cell-killing mechanism: a peer-reviewed publication from the laboratory of Nobel laureate Jennifer Doudna at the University of California, Berkeley featuring in vivo mouse model data, and another led by researchers at Utah State University and University of Utah Health. [ABSTRACT FROM PUBLISHER]
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=bwh&AN=bizwire.20260709876340
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Confluence Genetics Launches Cas-CLEAR™, a New CRISPR Technology Platform for Cancer Therapy
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Confluence Genetics
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 07
              Text: 07/09/2026
              Type: published
              Y: 2026
          Titles:
            – TitleFull: Business Wire (English)
              Type: main
ResultId 1